Parameters for monitoring treatment effects in CIDP with anti-MAG/SGPG IgM antibody.
We used cycles of plasma exchange and intravenous cyclophosphamide to treat a patient who had chronic inflammatory demyelinating polyneuropathy with anti-myelin-associated glycoprotein/sulfoglucuronylparagloboside IgM antibody. After treatment, serum anti-sulfoglucuronylparagloboside IgM antibody titers were reduced significantly, and clear symptomatic improvement followed. The percentage of CD57-positive lymphocytes and natural killer cell activity had also returned to normal. Our findings indicate that serial measurements of these parameters are useful for monitoring treatment effect in this disease.
Tagawa
Y
Y
Department of Neurology, Dokkyo University School of Medicine, Tochigi, Japan. ytagawa@jhmi.edu
Yuki
N
N
Ohnishi
A
A
Hirata
K
K
Hosokawa
S
S
D019138:Antibodies, Blocking / Q000627:therapeutic use*; D018959:CD57 Antigens / Q000276:immunology; D003520:Cyclophosphamide / Q000627:therapeutic use; D003711:Demyelinating Diseases / Q000175:diagnosis / Q000503:physiopathology / Q000628:therapy*; D004568:Electrodiagnosis; D005915:Globosides / Q000276:immunology*; D006801:Humans; D007075:Immunoglobulin M / Q000627:therapeutic use*; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D007694:Killer Cells, Natural / Q000276:immunology; D008297:Male; D008875:Middle Aged; D013497:Sural Nerve / Q000473:pathology
D019138:Antibodies, Blocking; D018959:CD57 Antigens; D005915:Globosides; D007075:Immunoglobulin M; D007166:Immunosuppressive Agents; C051917:sulfate-3-glucuronyl paragloboside; D003520:Cyclophosphamide